Direct factory batch supply for metabolic, neurological, and short bowel therapeutics tailored for Philippine clinical development initiatives.
Strategic alignment with the Philippine National Health Research System (PNHRS) and expanding clinical trial hubs across Bonifacio Global City, Quezon City, and Alabang.
With type-2 diabetes and metabolic disorders affecting over 4 million Filipinos, demand in Metro Manila for high-purity GLP-1 analogues, dual agonists, and synthetic human growth hormone analogues has grown exponentially among clinical researchers, clinical trial organizations (CROs), and compounding institutions.
Traditionally dependent on fragmented secondary API brokers, Manila's biopharma developers often confront high batch variations, unreliable cold-chain transshipments via NAIA, and non-traceable analytical documentation. Direct CDMO synthesis bypasses intermediary volatility.
The Food and Drug Administration (FDA) Philippines is progressively harmonizing quality requirements with ASEAN CTD standards. Procurement leads require complete HPLC, LC-MS, residual solvent data, and validated elemental impurity profiling to support local dossier filings.
Comprehensive solid-phase (SPPS), liquid-phase (LPPS), and hybrid fragment condensation platforms meeting international pharmacopeial limits.
Advanced Fmoc/tBu and Boc synthesis methodologies ensuring precise coupling efficiency for long peptides and sterically hindered amino acid sequences.
Dual-stage axial compression preparative chromatography removing deletion peptides, diastereomers, and beta-sheet aggregates to achieve purities up to 99.5%.
Optimized freeze-drying cycles ensuring low water content, specified counter-ion exchange (Acetate vs. TFA removal), and exceptional physical reconstitution stability.
Complete CMC dossier compilation, method validation reports, stability profiles (accelerated and long-term), and regulatory support tailored for FDA Philippines submission.
Connect directly with our senior peptide chemists and regional Asia-Pacific desk to receive tailored technical quotes, target specification reviews, and current lot chromatograms.
Send Inquiry NowSupplying validated therapeutic substances, neuroprotective peptides, and tissue repair factors with full traceability and batch stability.
Clear, direct answers regarding cold-chain stability, documentation, regulatory frameworks, and custom synthesis timelines.
Peptide APIs are shipped under validated cold-chain conditions utilizing vacuum insulated panels (VIP) and conditioned PCM (Phase Change Material) coolants maintaining -20°C or 2-8°C environments. Real-time temperature loggers are included with each transit into Ninoy Aquino International Airport (MNL), ensuring absolute sequence integrity through customs clearance.
Every commercial and custom lot is accompanied by a comprehensive Certificate of Analysis (CoA) containing analytical RP-HPLC purity traces, ESI-MS/MALDI-TOF mass spectrometry identity, net peptide content via Nitrogen/AAA analysis, residual solvents (ICH Q3C), endotoxin levels (<5 EU/mg for clinical injectables), and heavy metal traces.
Yes. While TFA is standard for crude synthesis, therapeutic and in-vivo clinical applications in the Philippines frequently require acetate or hydrochloride counter-ions to avoid cellular cytotoxicity. We perform ion-exchange chromatography achieving residual TFA levels below 0.1% or non-detectable thresholds.
Standard lead times for catalog APIs are 3-5 business days for immediate dispatch. For de novo custom sequence synthesis (from milligram feasibility to kilogram GMP batches), cycle times typically range between 3 to 6 weeks, which includes full synthesis, preparative purification, lyophilization, and multi-test QA validation.
You can directly contact our Asia-Pacific desk via our inquiries page or WhatsApp. Specify your target CAS number or amino acid sequence, target purity (≥95%, ≥98%, or ≥99%), desired salt form, and annual volume to receive an itemized quotation within 24 hours.
Thin